Analysts' Actions: LB MYGN SP EXPE

NEW YORK (TheStreet) -- CHANGE IN RATINGS

L Brands (LB) was downgraded to hold at TheStreet Ratings.

Myriad Genetics (MYGN) was downgraded from market perform to underperform at JMP Securities. Twelve-month price target is $15. BRCA pricing is lower than expected, JMP Securities said.

SP Plus (SP) was upgraded to buy at TheStreet Ratings.

[Read: 4 Stocks Ready for Breakouts]

Stock Comments / EPS Changes

Expedia's (EXPE) 12-month price target was raised at Cantor Fitzgerald. Shares are now seen reaching $75. Checks point to higher site visitation in recent months, Cantor Fitzgerald said. Buy rating.

[Read: What Supplemental Health Care Has Been Costing Us]

Follow TheStreet on Twitter and become a fan on Facebook.

This article was written by a staff member of TheStreet.

More from Stocks

GE Is Too Opaque, Too Diversified and Too Poorly Managed: Doug Kass Insider

GE Is Too Opaque, Too Diversified and Too Poorly Managed: Doug Kass Insider

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Google's YouTube in Hot Water Again Over Ads on Inappropriate Content

Google's YouTube in Hot Water Again Over Ads on Inappropriate Content

Should Tesla Nominate a New CEO Not Named Elon Musk?

Should Tesla Nominate a New CEO Not Named Elon Musk?